Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MPV

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: MPV. Displaying page 1 of 1.
    EudraCT Number: 2013-000320-33 Sponsor Protocol Number: HOVON_123_MM Start Date*: 2013-11-14
    Sponsor Name:HOVON Foundation
    Full Title: Feasibility and Efficacy of dose adjusted Melphalan – Prednisone – Bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed Multiple Myeloma; a nonrandomised phase II study
    Medical condition: Newly diagnosed symptomatic Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-001729-26 Sponsor Protocol Number: CC-5013-MM-026 Start Date*: 2014-03-25
    Sponsor Name:Celgene Corporation
    Full Title: Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma
    Medical condition: Newly diagnosed multiple myeloma (NDMM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003632-23 Sponsor Protocol Number: IC2019-02 Start Date*: 2020-06-17
    Sponsor Name:Institut Curie
    Full Title: LOC-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 with a newly diagnosed...
    Medical condition: Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018379-70 Sponsor Protocol Number: GEM2010MAS65 Start Date*: 2010-07-21
    Sponsor Name:Fundación PETHEMA
    Full Title: Estudio Fase IIb Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de tratamiento con un esquema secuencial Melfalán/Prednisona/Bortezomib (Velcade®) (MPV) seguido de Lenalidomida (Revlimi...
    Medical condition: MIELOMA MÚLTIPLE
    Disease: Version SOC Term Classification Code Term Level
    11 10028228 Mieloma múltiple LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006084-23 Sponsor Protocol Number: P060239 Start Date*: 2007-05-28
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude multicentrique, randomisée , de phase II évaluant l'association méthotrexate et témozolomide (MT) à l'association méthotrexate, procarbazine, vincristine et cytarabine (MPV-A) dans le traitem...
    Medical condition: Lymphome Primitif du Système Nerveux Central (LPSNC) chez le sujet âgé
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007953 Lymphome Primitif du Système Nerveux Central PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002157-29 Sponsor Protocol Number: 3 Start Date*: 2015-01-20
    Sponsor Name:Ernesto Pérez Persona
    Full Title: Clinical, multicenter, single-arm, with a scheme of treatment with low doses of Bortezomib / Melphalan / Prednisone (Velcade) (MPV) in patients with multiple myeloma (MM) newly diagnosed symptomati...
    Medical condition: multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10028566 Myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003842-18 Sponsor Protocol Number: OTL-103-4 Start Date*: 2019-01-08
    Sponsor Name:Orchard Therapeutics Ltd.
    Full Title: A Single Arm, Open Label Clinical Study of Haematopoietic Stem Cell Gene Therapy with Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector encoding WAS cDNA in Subjects with Wisko...
    Medical condition: Wiskott-Aldrich Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10061598 Immunodeficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000586-72 Sponsor Protocol Number: NMSG#25/16 Start Date*: 2017-10-10
    Sponsor Name:Oslo University Hospital
    Full Title: KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) SE (Prematurely Ended) PT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 04:37:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA